At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
MT-2990 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of MT-2990 in Women With Endometriosis Experiencing Endometrial Related Pain
In Brief
A Phase 2 clinical trial evaluating MT-2990 and Placebo for Endometrial Related Pain. Completed, enrolled 76 participants across 51 sites.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Related Pain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJan 2019
First PostedFeb 2019
Primary CompletionMay 2021
Study CompletionOct 2021
TodayJul 2026
First PostedFeb 15, 2019
Enrollment StartJan 15, 2019
Primary CompletionMay 13, 2021
Study CompletionOct 5, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.4 years ago
Interventions
MT-2990drug
over 16 weeks
Placebodrug
over 16 weeks